Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLN +5.56%56 Days Payable is 33.38 as of Mar. 2026, which is 29% above its 10-year median of 25.85. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Starling Oncology ranks worse than 73.72% on this metric.
The historical rank and industry rank for Starling Oncology's Days Payable or its related term are showing as below:
STLN'
s Days Payable Range Over the Past 10 Years
Min: 16.41 Med: 25.85 Max: 31.74
Current: 30.05
During the past 8 years, Starling Oncology's highest Days Payable was 31.74. The lowest was 16.41. And the median was 25.85.
STLN's Days Payable is ranked worse than 73.72% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: 56.95
vs STLN: 30.05
Starling Oncology's Days Payable
increased
from Mar. 2025 (28.07) to Mar. 2026 (33.38).
It may suggest that Starling Oncologydelayed paying its suppliers.
The historical data trend for Starling Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Starling Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Starling Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Starling Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starling Oncology (STLN) has a Days Payable of 33.38 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Starling Oncology and its competitors. This is 29% above median its historical median of 25.85. Over the past decade, Starling Oncology's Days Payable has ranged from 16.41 to 31.74. According to the industry distribution chart, Starling Oncology ranks #446 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 73.7%.
Is Starling Oncology's Days Payable too high?
Starling Oncology's current Days Payable of 33.38 is 29% above median its 10-year median of 25.85. Over the past 10 years, this metric has ranged from a low of 16.41 to a high of 31.74. The Healthcare Providers & Services industry median Days Payable is 56.95. Starling Oncology's value of 33.38 is 41.4% below this industry median. Based on the distribution chart, Starling Oncology ranks #446 out of 605 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Days Payable compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #446 out of 605 companies for Days Payable. This places Starling Oncology in the lower half of its industry. The industry median Days Payable is 56.95. Starling Oncology's value of 33.38 is 41.4% below this benchmark. Historically, Starling Oncology's own Days Payable has ranged from 16.41 to 31.74 over the past decade. While the company's 10-year median is 25.85 vs. the industry median of 56.95, Starling Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 56.95, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starling Oncology's current Days Payable of 33.38 is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 56.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current Days Payable is 33.38, which is 29% above median its own 10-year median of 25.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current Days Payable is 33.38, which is 29% above median its 10-year median of 25.85 and 41.4% below the Healthcare Providers & Services industry median of 56.95. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Starling Oncology (STLN), the current Days Payable is 33.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starling Oncology (STLN) Overvalued in 2026?
Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued.
The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29.
GuruFocus considers Starling Oncology to be Significantly Overvalued.
Key valuation signals for STLN:
Days Payable: 33.38 (29% above median its 10-year median of 25.85)
GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
Industry Position: 41.4% below the Healthcare Providers & Services median (#446 of 605)
No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for STLN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLN has been successfully added to your 
